The complement cascade plays a vital role in the immune response but can have harmful effects if dysregulated. Complement therapeutics offer a way to modulate this cascade, prevent terminal pathway formation, and mitigate cell damage. By targeting specific proteins, complement therapeutics effectively regulate the complement cascade's inflammatory and opsonic properties.
Assessing CDC activity during the development process offers several benefits. CDC is initiated by fixed C1q – the classical pathway's initiating component - and requires central components like C3 and C5 to occur. Inhibiting these components with complement-targeting therapeutics will impact CDC activity. Assessing CDC provides rapid and robust data on the complement-targeting therapeutic's ability to prevent cell lysis.
Understanding CDC and its role in complement therapeutics is vital for the development of effective treatments. By targeting the complement cascade and evaluating therapeutic activity through the innovative iLite CDC bioassay, scientists can ensure truly reflective Mechanism of Action (MoA) assessment and unlock new possibilities in the field of anti-complement therapies.
